Grupo Fleury (B3: FLRY3), Brazil’s largest diagnostic medicine and health services company, reported Q1 2026 net income of R$201.2 million ($40M), up 12.2 percent year-on-year and beating the LSEG consensus of R$192.5 million, according to the CVM filing released Thursday May 7.
Adjusted EBITDA reached R$606 million ($120M, +10.7%) at a stable 27.3 percent margin, with gross revenue of R$2.41 billion (+10.1%) and net revenue of R$2.223 billion (+10.3%), per the earnings release.
CEO Jeane Tsutsui told Broadcast that the company “begins its centennial year very strong” with double-digit growth across all key metrics, citing a strategy built on three pillars: organic growth, acquisitions, and financial discipline.
The Fleury brand grew 12.1 percent, São Paulo regional clinics expanded 28.1 percent, and the new Marco 100 premium unit — a R$35 million investment — opened this month.
Key Points
What Fleury Did in Q1 2026
Grupo Fleury is Brazil’s largest diagnostic medicine company, operating approximately 600 patient service points across multiple brands (Fleury, a+, Weinmann, Labs a+, Campana, Moacyr Cunha, among others) in São Paulo, Rio de Janeiro, Minas Gerais, Rio Grande do Sul, Paraná, Bahia, and other states. Founded in 1926 in São Paulo, the company celebrates its centennial in 2026. CEO Jeane Tsutsui — a cardiologist who assumed the role in April 2021 — has tripled revenue since 2017 through a combination of organic expansion, the transformational Pardini merger (completed 2023), and technology investment.
CEO Tsutsui attributed the result to “the differentiation of our services” plus macro tailwinds: formal employment growth expanding the privately insured population, aging demographics increasing diagnostic demand, and greater health consciousness post-pandemic, according to her Broadcast interview. The decision to exit Oncoclínicas/Porto Seguro exploratory talks after just three weeks (March 23 – April 13) signals capital discipline — Fleury evaluated the oncology expansion opportunity but determined it did not meet return thresholds in the current high-rate environment, per Reuters reporting.
Live Company IntelligenceFleury S.A. — the full investor dossier
Valuation & profitability
Price & risk
$13.0152-wk high
$20.11
Revenue trend · 6y
Ownership
Dividend
Why Fleury’s Q1 Matters for Healthcare
Fleury’s consistent double-digit growth in a high-rate environment where many consumer-facing companies are struggling is a data point about Brazil’s healthcare sector resilience. The company benefits from structural demand drivers that are largely independent of the business cycle: aging population, rising chronic disease burden, expansion of private health insurance coverage (driven by formal employment growth), and increasing diagnostic complexity. The 28.1 percent revenue growth in São Paulo regional clinics and 19.7 percent in Minas Gerais reflects geographic consolidation as smaller independent labs continue to be absorbed into the Fleury ecosystem. The Pardini integration — two years after closing — is now fully contributing to synergies, per CEO Tsutsui’s commentary.
Fleury Q1 2026 Snapshot
| Indicator | Q1 2026 | Chg YoY |
|---|---|---|
| Net Income | R$201.2M ($40M) — beat | +12.2% |
| EBITDA | Margin | R$606M ($120M) | 27.3% | +10.7% | Stable |
| Gross Revenue | R$2.41B ($477M) | +10.1% |
| Fleury Brand | R$621.2M | +12.1% |
| SP Regional | RJ | MG | — | +28.1% | +9.2% | +19.7% |
| Unit Rev (organic) | R$1.7B | +15.1% total (+11.8% organic) |
Frequently Asked Questions
Did Fleury beat Q1 expectations?
Yes. Net income of R$201.2 million beat the LSEG consensus of R$192.5 million by 4.5 percent. EBITDA of R$606 million grew 10.7 percent with a stable 27.3 percent margin. Revenue reached R$2.41 billion, up 10.1 percent, driven by the Fleury brand and São Paulo regional clinic expansion.
Why did Fleury drop the Oncoclínicas deal?
Fleury entered exploratory talks about a potential transaction with Porto Seguro and Oncoclínicas on March 23 but exited after a three-week evaluation window on April 13. CEO Tsutsui said Fleury already has a complete oncology diagnostic portfolio and the deal did not meet return thresholds in the current high-rate environment.
What is driving Fleury’s growth?
Three structural factors: aging population increasing diagnostic demand, formal employment growth expanding private insurance coverage, and Fleury’s geographic consolidation absorbing smaller independent labs. The Pardini merger integration is now complete after two years, contributing to synergies across the combined network of approximately 600 service points.
Updated: 2026-05-08T13:00:00-03:00 by Rio Times Editorial Desk
Fleury Q1 2026 | FLRY3 earnings | Brazil diagnostic medicine healthcare | Latin American financial news | The Rio Times
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Read More from The Rio Times